Loading clinical trials...

NOT_YET_RECRUITINGPHASE1/PHASE2

Feasibility of Fluorescence Imaging with Bevacizumab-800CW During Bronchoscopy

Feasibility of Fluorescence Imaging with Bevaci-zumab-800CW During Bronchoscopy in Patients with a Pulmonary Lesion Considered to Be Malignant

NCT06809946•University Medical Center Groningen

View on ClinicalTrials.gov

Summary

In this feasibility study, bronchoscopy will be combined with fluorescence molecular imaging using the near-infrared fluorescence (NIRF) tracer bevacizumab-800CW for assessment of pulmonary lesions and/or lymph nodes considered to be malignant.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Signed informed consent prior to participation in the study.
•2. Age ≥ 18 years.
•3. Patient has at least one intrabronchial, near-to-airway located or peripheral pulmonary nodule - with or without pathological lymph nodes - which is considered malignant (independent of its primary origin).
•4. Patient is considered fit to undergo a diagnostic and/or therapeutic bronchoscopy (with or without addition of virtual navigation and/or endobronchial ultrasound; including propofol sedation or general anesthesia if either is indicated) to obtain tumor material according to standard care protocols.

Exclusion Criteria

•1. History of infusion reactions to bevacizumab.
•2. Medical or psychiatric conditions that compromise the patient's ability to give informed consent.

Key Dates

Start Date

June 1, 2025

Primary Completion Date

June 1, 2026

Completion Date

December 1, 2026

Last Updated

February 20, 2025

Enrollment

ESTIMATED participants

Conditions

Lung NeoplasmsPulmonary NeoplasmsLymph Node Involvement

Interventions

injection with 15 mg bevacizumab-800CW before bronchoscopy

DRUG

injection with 25 mg bevacizumab-800CW before bronchoscopy

DRUG

Contacts

Frederike Bensch, MD, PhD

CONTACT

0031503610280 f.bensch@umcg.nl

LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada

NCT07143110

Lung Neoplasms

View study

RECRUITINGPHASE1

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT06885697

MesotheliomaNeoplasms+6 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 20, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Feasibility of Fluorescence Imaging with Bevacizumab-800CW During Bronchoscopy

Inclusion Criteria

Exclusion Criteria

LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques

Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC